This phase III trial is assessing the addition of andecaliximab to a combination chemotherapy as a first line treatment for people with advanced gastric or gastro-oesophageal cancers.
This trial is treating patients with Stomach (gastric) and Gastro-Oesophageal Junction Cancers.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Gilead Sciences, Inc.
The primary objective of this study is to compare the efficacy of GS-5745 versus placebo in combination with modified fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More